← Leaderboards
James Burnett
Illexcor Therapeutics, Llc
$599,962
Attributed
$599,962
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding mix
By agency
NIH$599,962 · 2
By mechanism
R43$599,962 · 2
Top collaborators
No co-investigators on record.
Most similar at Illexcor Therapeutics, Llc
Same institution · by research overlap
- David Richard Light$5,339,332
Others in their field
Other Emerging Leaders on “Hypoxia”
- Lori Shutter · University Of Michigan At Ann Arbor$7,883,569
- Sharon Dziuba Yeatts · University Of Michigan At Ann Arbor$7,883,569
- Nobuyuki Ishibashi · Children'S Research Institute$6,824,524
- David Richard Light · Illexcor Therapeutics, Llc$5,339,332
- Isha Himani Jain · University Of California, San Francisco$4,799,884
- Petter Bjornstad · University Of Colorado Denver$4,557,141
Research focus
HypoxiaOralDrug CandidateHourModificationMouse ModelCessation Of LifeDoseEfficacy StudyHemoglobinIn VivoLeadAntisickling AgentsAffinityAldehydesBindingBioavailableCost EstimateBiological AvailabilityAmericanErythrocytesHealthcare SystemsAffectOrgan
Grant awards (2)
Rapid Development of a Lead Aromatic Aldehyde Derivative with both Oxygen Dependent and Novel, Oxygen Independent Anti-Sickling Effects: Building on a Paradigm Shift in Sickle Cell Disease Therapy$300,000
R43 · FY2020 · HL · contact PI
Prodrugs and Derivatives of Hydroxymethylfurfural (5-HMF) to Develop a Novel, Bioavailable Treatment for Sickle Cell Disease$299,962
R43 · FY2020 · HL · contact PI